Clinical Trials

Accrual Status
Limit to SWOG Trials

1040 Results

View
Closed
Phase
Accrual
100%
Published
SWOG Clinical Trial Number
S0415

Cetuximab as a Second Line Therapy in Patients with Metastatic Esophageal Cancer - Phase II
Activated
10-15-2004
Closed
01-01-2007
Closed
Phase
Accrual
100%
Published
SWOG Clinical Trial Number
S0420

Phase II Evaluation of BAY 43-9006 (NSC-724772) in Patients with Recurrent or Metastatic Head and Neck Cancer
Research Committee(s)
Head and Neck Cancer
Activated
10-01-2004
Closed
Phase
Accrual
100%
Published
SWOG Clinical Trial Number
S0341

Phase II Trial of OSI-774 (NSC-718781) in Patients with Advanced Non-Small Cell Lung Cancer and a Performance Status of 2
Research Committee(s)
Lung Cancer
Activated
09-15-2004
Closed
10-01-2005
Closed
Phase
Accrual
100%
Published
SWOG Clinical Trial Number
S0356

Oxaliplatin Plus Protracted Infusion 5-Fluorouracil and Radiation for Potentially Curable Esophageal Cancer: A Phase II Trial with Molecular Correlates
Research Committee(s)
Gastrointestinal Cancer
Activated
09-15-2004
Closed
08-01-2008
Closed
Phase
Accrual
100%
Published
SWOG Clinical Trial Number
S0432

Phase II Studies of Two Different Schedules and Two Different Doses of the Farnesyl Transferase Inhibitor R115777 (Tipifarnib, Zarnestra�, NSC-702818)for Previously Untreated Acute Myeloid Leukemia (AML) in Patients of Age 70 or Older.
Research Committee(s)
Leukemia
Activated
09-15-2004
Closed
02-21-2006
Closed
Phase
Accrual
100%
Published
SWOG Clinical Trial Number
S0412

A Phase II Study of the RAF-Kinase Inhibitor BAY 43-9006 (NSC-724772, IND-69,896) in Combination with Interferon Alpha 2b in Patients wtih Advanced Renal Cancer
Research Committee(s)
Genitourinary Cancer
Activated
09-01-2004
Closed
05-15-2005
Closed
Phase
Accrual
1%
SWOG Clinical Trial Number
S0229

A Randomized Trial Assessing the Effects of Exercise on Patients with Locally Advanced Lung Cancer Undergoing Curative Intent Combined Modality Therapy
Research Committee(s)
Lung Cancer
Activated
09-01-2004
Closed
Phase
Accrual
100%
Published
SWOG Clinical Trial Number
S0325

A Phase IIb Study of Molecular Responses to Imatinib, at Standard or Increased Doses, or Dasatinib (BMS-354825) (NSC-732517) for Previously Untreated Patients With Chronic Myelogenous Leukemia (CML) in Chronic Phase.
Research Committee(s)
Leukemia
Activated
08-15-2004
Closed
02-28-2009
Closed
Phase
Accrual
0%
SWOG Clinical Trial Number
S0304

A Phase II Feasibility Translational Research Trial of Induction Chemotherapy Followed by Concomitant Chemoradiation in Patients with Clinical T3-T4 Rectal Cancer
Research Committee(s)
Gastrointestinal Cancer
Activated
08-01-2004
Closed
02-01-2006
Closed
Phase
Accrual
97%
Published
SWOG Clinical Trial Number
S0316

Barriers to Accrual to Clinical Trials in Older (>= 65 Years) Cancer Patients
Status Notes
Activated
08-01-2004
Closed
06-15-2008
Closed
Phase
Published
SWOG Clinical Trial Number
S0000B

Prevention of Cataract and Age-Related Macular Degeneration with Vitamin E and Selenium - SELECT Eye Endpoints (SEE)
Research Committee(s)
Other
Activated
07-01-2004
Closed
07-31-2015
Closed
Phase
Accrual
100%
Published
SWOG Clinical Trial Number
S0342

Phase II Selection Design Trial of Concurrent Chemotherapy + Cetuximab vs. Chemotherapy Followed by Cetuximab in Advanced Non-Small Cell Lung Cancer (NSCLC)
Research Committee(s)
Lung Cancer
Activated
07-01-2004
Closed
08-01-2005
Closed
Phase
Accrual
39%
Published
SWOG Clinical Trial Number
S0338

Phase II Trial of Imatinib Mesylate (Gleevec) (NSC-716051) In Combination With Capecitabine (Xeloda) (NSC-712807) In Metastatic Breast Cancer
Research Committee(s)
Breast Cancer
Activated
06-15-2004
Closed
12-15-2005
Closed
Phase
Accrual
15%
SWOG Clinical Trial Number
S0400

A Phase II Study of Depsipeptide (NSC-630176) in Patients with Advanced Transitional Cell Carcinoma of the Urinary Tract Who Have Progressed After Receiving One Prior Chemotherapy Regimen for Advanced Disease
Research Committee(s)
Genitourinary Cancer
Activated
06-15-2004
Closed
04-15-2006
Closed
Phase
Accrual
94%
Published
SWOG Clinical Trial Number
S0000C

Prevention of Lung Function Decline with Vitamin E and Selenium - Respiratory Ancillary Study (RAS) to SELECT
Research Committee(s)
Other
Activated
06-04-2004
Closed
05-01-2007
Closed
Phase
Accrual
20%
Published
SWOG Clinical Trial Number
S0345

A Phase II Study of Imatinib (NSC-716051) in Patients with Locally Advanced or Metastatic Dermatofibrosarcoma Protuberans
Research Committee(s)
Sarcoma
Activated
05-15-2004
Closed
12-15-2006
Closed
Phase
Accrual
93%
Published
SWOG Clinical Trial Number
S0106

A Phase III Study of the Addition of Gemtuzumab Ozogamicin (Mylotarg�) Induction Therapy Versus Standard Induction With Daunomycin and Cytosine Arabinoside Followed by Consolidation and Subsequent Randomization to Post-Consolidation Therapy With Gemtuzumab Ozogamicin (Mylotarg�) or No Additional Therapy for Patients Under Age 61 With Previously Untreated De Novo Acute Myeloid Leukemia (AML)
Research Committee(s)
Leukemia
Activated
05-15-2004
Closed
08-20-2009
Closed
Phase
Accrual
70%
Published
SWOG Clinical Trial Number
S0336

Phase II Trial of Depsipeptide (NSC-630176) in Colorectal Cancer Patients Who Have Received Either One or Two Chemotherapy Regimens for Metastatic or Locally Advanced, Unresectable Disease
Research Committee(s)
Gastrointestinal Cancer
Activated
04-15-2004
Closed
09-01-2005
Closed
Phase
Accrual
2%
SWOG Clinical Trial Number
S0303

A Phase III Trial of Modified FOLFOX6 versus CAPOX, with Bevacizumab (NSC-704865) or Placebo*, as First-Line Therapy in Patients with Previously Untreated Advanced Colorectal Cancer
Research Committee(s)
Gastrointestinal Cancer
Activated
04-01-2004
Closed
09-01-2004
Closed
Phase
Accrual
100%
Published
SWOG Clinical Trial Number
S0226

Phase III Randomized Trial of Anastrozole Versus Anastrozole and Fulvestrant as First Line Therapy for Post Menopausal Women With Metastatic Breast Cancer.
Status Notes
S0226 was completed on 10/1/2018. All patient follow-up has ended and the IND for this study was closed. Any remaining drug must be destroyed per institutional procedures and drug accountability records maintained per 21 CFR 312.62 and institutional procedures.
Research Committee(s)
Breast Cancer
Activated
04-01-2004
Closed
07-01-2009